Posters

Two year retrospective study of our first 46 cases with two second-generation trabecular micro-bypass stents

Poster Details

First Author: B.Gonzalez Ferrer SPAIN

Co Author(s):    R. Cordero Ros   C. Lavín-Dapena   A. Ramos Castrillo   J. Dabad Moreno   P. Fernández Pérez   C. Fernández Alcalde     

Abstract Details

Purpose:

To evaluate the efficacy of iStent Inject ® device (Glaukos, Laguna Hills, CA) associated or not with phacoemulsification in eyes with different types of glaucoma (Chronic open angle glaucoma, pseudoexfoliative glaucoma, narrow angle glaucoma, and pigmentary glaucoma).

Setting:

University Hospital La Paz, Madrid, Spain

Methods:

A retrospective interventional case series. All patients who were implanted with istent inject from April 2017 to November 2018 were included. Postoperatively, patients were assesed on days 1 and 7, and months 1 ,3 ,6 ,12 and 24. In each visit, intraocular pressure (IOP), visual acuity and the presence of complications were recorded.

Results:

Forty patients were included in this study. At 12 months after surgery mean IOP had fallen from 21.6 mmHg to 16.2, achieving 15.7 mmHg in those eyes whose follow-up was 24 months. Average medication usage was reduced from 1.8 to 0.2 medications. Over 80% of eyes became medication-free by 12 months post implantation, reaching 89% in the 19 patients reviewed two years after surgery. The most common postoperative complication was the implantation of just one istent. No significant intraoperative or postoperative complications were found.

Conclusions:

In our experience, iStent implantation produce a clinically significants IOP and medication reductions for at least 24 months after the surgery, showing a good safety profile.

Financial Disclosure:

None